octreotide acetate solution for injection / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   9 Trials   9 Trials   96 News 


123»
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    Journal:  Effective Control of Pancreatitis-Related Gastric Varices Through Splenic Artery Embolization: A Case Report. (Pubmed Central) -  Oct 17, 2024   
    The patient initially received medical management with IV sandostatin for bleeding control, and a splenectomy was planned as the definitive management...Splenic artery embolization led to a successful reduction in gastric variceal size and no recurrence of bleeding. This case report presents a case of pancreatitis-induced splenic vein thrombosis (PISVT) and highlights splenic artery embolization as a viable management strategy in such cases.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    CASE REPORT: A PATIENT WITH MULTIPLE PARAGANGLIOMA TREATED WITH LONG-ACTING SOMATOSTATIN ANALOGUE () -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_1041;    
    A case of recurrent metastatic paraganglioma is presented.After 1 year of treatment with LAR octreotide there is improvement in quality of life, reduction in hypertensive crisis and stroke admissions. Research should be continued for targeting SSTRs with second-generation SSAs,chimeric dual receptor-targeting peptides, chemotactic delivery through SSTRs, and other novel methods.
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    Preclinical, Journal:  Optimization and validation of the liquid chromatography coupled to tandem mass spectrometry method for assessing octreotide release from microspheres during inflammation in rabbit models. (Pubmed Central) -  Dec 13, 2022   
    To study the effect of acute-phase reaction (APR) of inflammation on the release of octreotide acetate microsphere (Sandostatin®, SLAR) at a clinical dose, a more sensitive liquid chromatography coupled to tandem mass spectrometry analysis method needs to be developed because of the low plasma concentrations of octreotide...The coefficients of variations for intraday and interday precision were less than 4.4 %, and the relative error of accuracy was within 5.7 %. The validated method was successfully applied to pharmacokinetics studies of SLAR in a seven-day inflammation model of rabbits, indicating that the APR did not affected the release and pharmacokinetics of the octreotide microspheres.
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    The Role of 68Ga-DOTATATE PET/CT in the Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors () -  Nov 8, 2022 - Abstract #NANETS2022NANETS_190;    
    Of these, 27 patients had a change in medical management with 26 patients starting systemic therapy such as PRRT, chemotherapy or sandostatin and 1 patient being down-staged and taken off sandostatin, 9 patients had a change in surgical management with 7 patients undergoing a surgical resection due to primary or metastatic lesion detection and 2 patients having cancellation of planned primary tumor resection...CONCLUSIONS Our retrospective study demonstrates that 68Ga-DOTATATE PET/CT resulted in a change in therapeutic management in 36.2% of patients with GI or pancreatic NET and improved lesion detection over conventional imaging in 48.4% of patients. This supports its use in the care of patients with GI and pancreatic NETs
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    Journal:  Minimizing the initial burst of octreotide acetate based long-acting microspheres by the solvent evaporation method. (Pubmed Central) -  Aug 18, 2022   
    Sandostatin long-acting release (SLAR) depot for 1-month controlled release of octreotide is a somatostatin analogue product that has been used extensively in the pharmacological treatment of acromegaly...Analysis of kinetics of dry Tg of the formulations reflected (a) the elevated residual solvent in SLAR and was not duplicated in the solvent evaporation formulations, and (b) the slightly higher Tg of peptide loaded formulations relative to than blank microspheres, consistent with the interaction of the acetate salt of octreotide with linear PLGA chains in the PLGA-glu. These data indicate that it is possible to prepare peptide loaded microspheres by the solvent evaporation method with extraordinarily similar performance to microspheres, such as those in SLAR, that are prepared by the low-burst release coacervation method.
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    Trial completion, Surgery:  Investigation of the Effects of Obesity Surgery on Appetitive Behaviour (clinicaltrials.gov) -  May 23, 2022   
    P=N/A,  N=30, Completed, 
    Larger case series are warranted to clarify the management of NICTH patients with placebo-controlled studies to determine the role of somatostatin analogues. Recruiting --> Completed
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method. (Pubmed Central) -  Apr 9, 2022   
    Key formulation steps identified to maximize microsphere yield and minimize residual solvent and initial burst release included (a) addition of acetic acid to the peptide before preparation and (b) annealing the microspheres under vacuum after drying. Controlled release octreotide formulations prepared and investigated in this study could provide a better understanding of the effect of production variables on release performance and supply information useful for making progress in manufacturing of SLAR generic equivalents.
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Trial completion date, Trial primary completion date:  Treatment of Orthostatic Intolerance (clinicaltrials.gov) -  Sep 8, 2021   
    P1/2,  N=150, Active, not recruiting, 
    Cette efficacité doit cependant étre confirmée dans un essai thérapeutique. Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    Primary Hepatic Neuroendocrine Tumor (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_2037;    
    We present a case of PHNET treated with sandostatin and locoregional therapy with the possibility of orthotopic liver transplant (OLT) with treatment failure...OLT may be a last line option in certain instances.Figure: Figure 1. Multiple hepatic lesions initially concerning for metastatic disease or HCC, later confirmed at PHNET.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    A Case of Ménétrier's Disease Treated With Cetuximab (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_223;    
    4: Endoscopic ultrasound demonstrating marked polypoid thickening of the gastric wallFig. 5: Photomicrograph showing proliferation of foveolar epithelium resulting in elongated, branched pits and dilated glands
  • ||||||||||  Sandostatin (octreotide acetate solution for injection) / Novartis
    Clinical, Journal:  Comparative scRNA-seq Reveals Liver Metastasis-Specific Targets in a Patient with Small Intestinal Neuroendocrine Cancer. (Pubmed Central) -  May 28, 2021   
    The patient eventually progressed on sandostatin and although consideration was given to adding an angiogenesis inhibitor to her regimen, her disease progression involved non-liver metastases which had not been characterized. Although in this specific case comparative scRNA-seq did not alter treatment, its potential to help guide therapy of metastatic disease was clearly demonstrated.
  • ||||||||||  Sandostatin (octreotide acetate solution for injection) / Novartis
    [VIRTUAL] A Case of Ileocecal and Distal Sigmoid Carcinoid Tumor With Liver Metastasis () -  Sep 15, 2020 - Abstract #ACG2020ACG_3250;    
    The patient was treated with Sandostatin injections monthly with significant clinical improvement, and is followed by Oncology and Gastroenterology services...Recent literature reports that the overall incidence of carcinoid tumors has been steadily increasing likely due to advances in testing, however most cases are being detected after wide-spread disease.CONCLUSION. Further description of the biological and histopathological characteristics of carcinoid tumors is needed for implementation of early detection techniques.
  • ||||||||||  Sandostatin (octreotide acetate solution for injection) / Novartis, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Characterization of branched poly(lactide-co-glycolide) polymers used in injectable, long-acting formulations. (Pubmed Central) -  Sep 11, 2020   
    The Mark-Houwink plots were also used to distinguish different Glu-PLGAs. These ensemble identification methods indicate that the branch units of Glu-PLGAs extracted from Sandostatin LAR range from 2 (i.e., linear) at the lower end of the molecular weight to <4 for the majority (94%) of Glu-PLGA.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Afinitor (everolimus) / Novartis
    [VIRTUAL] Carcinoid Causing Catastrophic Calcemia () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2432;    
    He was switched to Everolimus but did not respond to that and was readmitted mere weeks later for symptomatic hypercalcemia and a combination of Folinic acid, Fluorouracil, and Oxaliplatin (Folfox) was started...This patient had a rare tumor, producing an uncommon hormone, and required extensive treatment. This case shows the importance of a multidisciplinary approach in patients with hypercalcemia secondary to carcinoid tumors but refractory to traditional therapy.
  • ||||||||||  Sandostatin (octreotide acetate solution for injection) / Novartis
    [VIRTUAL] A Case of Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone (GHRH) Secretion from a Bronchial Neuroendocrine Tumour () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2415;    
    She was treated with intramuscular sandostatin 20mg q28days and then underwent a left pneumonectomy, resulting in biochemical resolution of her acromegaly (IGF-1 219 μg/L)...Learning points Diagnosis of acromegaly due to ectopic GHRH secretion requires high clinical suspicion by the treating clinicians (e.g., endocrinologist, oncologist) as well as review of histology by expert pathologists. Our case highlights that ectopic GHRH secretion is a rare but important cause of acromegaly, which should always be suspected when a clear pituitary cause is not identified.
  • ||||||||||  Octreosphere (octreotide extended release) / Xbrane, Sandostatin LAR Depot (octreotide acetate) / Novartis, adecatumumab (MT201) / Amgen
    [VIRTUAL] Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1360;    
    Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    Trial completion:  Stress, Diurnal Cortisol, and Breast Cancer Survival (clinicaltrials.gov) -  Nov 22, 2019   
    P=N/A,  N=115, Completed, 
    Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume. Active, not recruiting --> Completed
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Trial completion date, Trial primary completion date:  Treatment of Orthostatic Intolerance (clinicaltrials.gov) -  Aug 21, 2019   
    P1/2,  N=150, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022